It's Time to Start Phenotyping Our Patients with Asthma
It's Time to Start Phenotyping Our Patients with Asthma
复制标题
DOI：
10.1016/j.iac.2019.07.009
复制
发表时间：
2019-11-01
影响因子：
2.6
通讯作者：
Anderson, William C., III
中科院分区：
文献类型：
--
作者：
Duffey, Hannah;Anderson, William C., III
儿科哮喘管理的进步，包括生物制剂，使从业者能够为个体患者量身定制治疗。然而，哮喘治疗指南并没有跟上目前的研究。本综述探讨了目前的文献纳入使用表型在儿童哮喘患者提供精确的治疗。生物标志物可用于更准确地预测哮喘的发展，识别可能与难以控制或严重哮喘相关的特征，并预测对治疗的反应。生物标志物和其他表型数据也可以帮助不受控制的严重哮喘患者选择生物治疗。
Advances in the management of pediatric asthma, including biologics, offer practitioners the ability to tailor therapies to individual patients. However, asthma treatment guidelines have not kept up with current studies. This review explores the current literature incorporating the use of phenotyping in pediatric patients with asthma to provide precision therapy. Biomarkers can be used to more accurately predict the development of asthma, identify features that may be associated with difficult-to-control or severe asthma, and forecast response to therapies. Biomarkers and other phenotypic data can also be helpful in patients with uncontrolled, severe asthma in the selection of a biologic therapy.